Clinical Trial Update: Efficacy and Safety of Sintilimab Combined With Lenvatinib and HAIC for Neoadjuvant Therapy of Borderline Resectable HCC [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of sintilimab in combination with lenvatinib and hepatic arterial infusion chemotherapy as neoadjuvant ther…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• Sintilimab (sintilimab)

Snippet

Sponsor: Lei ZHAO | Conditions: HCC | Phase 2 | Status: RECRUITING